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Canine degenerative myelopathy (DM) is a progressive disease process that is diagnosed 
late in life and mainly affects the pelvic limbs. Factors that make an ante-mortem definitive 
diagnosis of DM include: an insidious onset and clinical manifestation that mimics other 
disease processes of the pelvic limbs (hip dysplasia, cranial cruciate ligament rupture, etc.) or 
there may even be concurrent disease processes, old-age onset and lack of reliable diagnostic 
methods. Until recently, South African dog owners had to submit samples to laboratories 
overseas for genetic testing in order to confirm an affected dog (homozygous A/A) and to 
aid in the ante-mortem diagnosis of DM. Only affected dogs have been confirmed to manifest 
the clinical signs of DM. This study aimed to verify whether genetic testing by a local genetic 
laboratory was possible in order to detect a missense mutation of the superoxide dismutase 
gene (SOD1) that is implicated in causing the clinical signs of DM. The study also aimed 
to detect and map the inheritance of this disease process in a local Boxer dog population 
where the pedigree of the sampled population was known. Venous blood collected from 
Boxer dogs using a simple random sampling technique. The samples were genotyped for the 
SOD1:c.118G>A polymorphism. Carrier and affected Boxer dogs were detected. A pedigree 
that demonstrated the significance of inheriting a carrier or affected state in the population was 
mapped. The present study concludes that genotyping of the missense mutation in Boxer dogs 
is possible in South Africa. There are carrier and affected Boxer dogs in the local population, 
making DM a plausible diagnosis in aged dogs presenting with pelvic limb pathology.
Introduction
Clinical and pathological findings of degenerative myelopathy (DM) were first described in the 
German Shepherd dog by Averill (1973). In the earlier descriptions of this disease process, canine 
DM has also been called chronic degenerative radiculomyelopathy (Griffiths & Duncan 1975), 
German Shepherd dog myelopathy (Braund & Vandevelde 1978) and progressive myelopathy 
(Waxman, Clemmons & Hinrichs 1980). Early investigation of the clinical manifestations of DM, 
which were most often recognised in the German Shepherd dog, suggested an inherent breed 
genetic  predisposition  (Braund  &  Vandevelde  1978).  Investigation  into  leukocyte  behaviour 
suggested an autoimmune-based aetiology (Waxman, Clemmons & Hinrichs 1980). Hereditary 
factors  were  suspected  when  DM  was  described  in  closely  related  Siberian  Husky  dogs 
(Bichsel et al. 1983). To date, DM has been diagnosed in many different dog breeds (Coates & 
Wininger 2010). The five most frequently diagnosed dog breeds with DM are German Shepherd 
dogs, Pembroke Welsh corgis, Boxer dogs, Rhodesian ridgebacks and Chesapeake Bay retrievers 
(Awano et al. 2009; Coates et al. 2007).
Characteristic clinical presentation of DM includes: an insidious, progressive onset of asymmetric 
upper motor neuron (UMN) paraparesis; general proprioceptive pelvic limb ataxia; and lack 
of paraspinal hyperaesthesia (Awano et al. 2009; Coates et al. 2007; Coates & Wininger 2010). 
These clinical signs are typical of the early stages of DM and may also include worn nails, spinal 
reflexes consistent with UMN paresis localised in the T3 to L3 spinal cord segment (Averill 1973), 
inconsistent patella reflex (normal, hyporeflexia, hyperreflexia) and normal withdrawal reflexes 
that may demonstrate crossed extension, which is suggestive of a chronic UMN dysfunction. 
Owners often elect euthanasia when the clinical signs progress to a non-ambulatory paraparesis 
(Awano et al. 2009; Coates & Wininger 2010). Clinical signs will progress in the late stage of 
DM and include lower motor neuron paraplegia that may ascend to the thoracic limbs (Averill 
1973; Awano et al. 2009; Coates et al. 2007; Coates & Wininger 2010). Flaccid tetraplegia, possible 
involvement of the cranial nerves presenting as swallowing difficulties and inability to bark, 
urinary and faecal incontinence, and muscle mass loss may occur in the very advanced stages 
(Averill 1973; Awano et al. 2009; Coates et al. 2007; Coates & Wininger 2010). The mean age 
of onset and mean duration of clinical signs in the Boxer dog are 9.3 years and 11.2 months 
respectively (Coates & Wininger 2010). Mean age of death in the Boxer dog is 10.3 years (Coates 
& Wininger 2010).
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Advances in molecular genetics have progressed to genome-
wide association mapping of DM using the Canine Genome 
(GeneChip  Canine  Genome  2.0  Array;  Affymetrix,  USA) 
(Awano et al. 2009). The strongest association was detected 
in  the  chromosome  of  Canis  familiaris  31  (CFA31),  where 
a  mutation  of  the  gene  encoding  superoxide  dismutase 
1  (SOD1)  was  mapped  and  localised  to  a  5-SNP  (single 
nucleotide  polymorphism)  haplotype.  The  area  of  the 
genome contains the E40K missense mutation that predicts 
a G to A transition in exon 2, corresponding to nucleotide 
118 of the complementary DNA (cDNA). This area is thought 
to be responsible for encoding a defect in the SOD1 amino 
acid chain (Awano et al. 2009). The defect is where a glutamic 
acid to lysine missense mutation at amino acid 40 (Coates 
& Wininger 2010) is predicted. Dogs may be genotyped into 
three different categories, based on the genotypic expression 
of the SOD1:c.118 allele, namely: unaffected, carrier, or at-
risk or affected (Awano et al. 2009; Coates et al. 2007; Coates 
& Wininger 2010).
The  present  study  was  aimed  at  detecting  carrier  and/or 
affected Boxer dogs of DM in the South African population 
using a SOD1:c.118G>A genetic test that had recently been 
developed  in  South  Africa.  This  article  also  discusses  the 
potential clinical relevance within a South African context.
Materials and Methods
The  prospective,  owner-consented,  blind,  observational 
study was approved by the Animal Use and Care Committee 
of the University of Pretoria (Protocol V005-13).
Animals
A targeted sample size of 50 Boxer dogs was genotyped for 
the  SOD1:c.118G>A  polymorphism.  No  exclusion  criteria 
on age, sex or pedigree were enforced. A history of prior 
hind limb pathology and gait abnormalities was obtained to 
determine possible phenotypic expression of DM. A simple 
random  sampling  technique  was  used  where  the  owners 
were made aware of the study 2 weeks prior to the sample 
collection and were allowed to enrol their dog or dogs at their 
own will on the day of sample collection. It was prohibited 
to encourage, promote or entice the owners to participate in 
the study.
Sample collection and storage
Boxer  dogs  were  sampled  at  two  dog  show  days  hosted 
by  clubs  affiliated  with  the  Federation  of  Boxer  Clubs  of 
Southern Africa (FBCSA). An owner-signed consent form and 
dog pedigree registration certificate showing the last three 
generations  was  required  before  sampling.  Venous  blood 
(2 mL) was aseptically collected from either the left or right 
cephalic vein using a syringe and needle. The collected sample 
was transferred to a vacuumed Ethylenediaminetetraacetic 
acid (EDTA) collection tube and stored on ice in a cooler 
box. Upon return to the University, the samples were stored 
overnight in a refrigerator before being transported on ice in 
a cooler box to the genetic testing laboratory. The number of 
dogs participating in the two shows and an estimated Boxer 
dog  population  size  based  on  the  FBSCA  database  were 
determined.
Genotyping of the superoxide dismutase 
gene:c.118 allele
The genetic testing laboratory (Inqaba Biotec, South Africa) 
developed  an  in-house  DM  test,  which  was  based  on 
literature published on the canine SOD1 gene (Awano et al. 
2009). The genetic testing laboratory synthesised their own 
oligonucleotides  used  for  testing,  based  on  the  sequences 
published by Awano et al. (2009). DNA was extracted and 
purified using a kit (Zymo Research Quick-gDNA MicroPrep 
kit, Zymo Research Corporation [USA] 17062 Murphy Ave. 
Irvine,  CA  92614).  A  polymerase  chain  reaction  (PCR) 
amplification  was  carried  out  on  a  cycler  (ABI  GeneAmp 
PCR  system  9700  thermal  cycler;  Applied  Biosystems)  to 
amplify the gene of interest. The cycle conditions are given in 
Table  1.  Thereafter,  the  amplicons  were  sequenced  on 
an  analyser  (ABI  PRIS  3130  Genetic  Analyzer;  Applied 
Biosystems)  to  determine  the  nucleotide  sequence  of  the 
gene.  Boxer  dogs  were  genotyped  into  three  different 
categories,  namely:  clear  or  unaffected  (homozygous 
G/G), carrier (heterozygous A/G), and at-risk or affected 
(homozygous A/A) based on the genotypic expression of 
the  SOD1:c.118  allele.  Where  applicable,  the  registration 
certificate information of the pedigree was used to describe 
the hereditary nature of the mutation in the SOD1 gene in the 
sampled population.
Statistical analysis
The age of the sampled Boxer dog population was described 
as  median  (maximum-minimum)  in  years.  A  spreadsheet 
software  package  (Microsoft  Office  Excel  2007;  Microsoft 
Corporation  USA)  was  used  to  organise  and  calculate 
information from the data collected. Point prevalence of dogs 
genotyped as affected for the SOD1 mutation in the FBCSA 
Boxer dog population was calculated as follows: number of 
dogs genotyped as being affected when sampled on the show 
day divided by the total number of dogs participating in the 
show on the sample day; this number was then converted 
into a percentage. Overall prevalence of affected genotyped 
dogs was calculated as follows: known number of affected 
genotyped  Boxer  dogs  divided  by  the  estimated  FBCSA 
dog  population.  This  number  was  then  converted  into  a 
percentage.
Results
A  total  of  52  (29  female,  23  male)  Boxer  dogs  were  tested. 
The sample  population  had  a  median  median  age  of  2.7 
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TABLE 1: PCR Cycle conditions.
Phase of complete cycle Temperature Time
Phase 1 (1 cycle) 98 °C    3 min
Phase 2 (30 cycles) 98 °C 15 s
59 °C 75 s
72 °C 30 s
Phase 3 (1 cycle) 72 °C 5 minOriginal Research
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(maximum  of  9.7;  minimum  of  0.53)  years. The numbers 
of clear, carrier and affected Boxer dogs are summarised in 
Table 2. The percentages of dogs sampled per show were 
72.7% and 68.3% for show day 1 and show day 2 respectively.
The hereditary nature of DM was detected in one line of 
Boxer dogs that were sampled (Figure 1). The progeny of the 
only affected dog genotyped during the data collection were 
subsequently tested and an additional five affected dogs were 
detected. The owner of the affected dog did indicate a history 
of pelvic limb abnormalities that had not been definitively 
diagnosed as DM, instead cranial cruciate ligament injury 
was suspected on cursory clinical examination.
Point  prevalence  of  Boxer  dogs  genotyped  as  affected  were 
3.03% and 0.00% for show day 1 and show day 2 respectively. 
Based on current database information, the estimated FBCSA 
population is 2650 Boxer dogs. Current overall prevalence 
of affected Boxer dogs within the FBCSA dog population is 
estimated ([1 affected + 5 affected progeny/2650] x 100) at 
0.23%. 
Discussion
The  present  study  determined  that  the  recently  available 
genetic  test  for  canine  DM  in  South  Africa  was  able  to 
genotype the SOD1:c.118 allele in a Boxer dog population. 
Clear,  carrier  and  affected  Boxer  dogs  were  identified 
despite  none  of  them  demonstrating  typical  clinical  signs 
of DM on examination. Enquiring about past pelvic limb or 
gait abnormalities suggested acute injuries to the stifle joint, 
with cranial cruciate ligament injury as the most common 
historical finding.
The DM associated SOD1:c118A homozygous (affected) allele 
has been identified in no less than 91 different dog breeds 
(Coates & Wininger 2010). Despite identifying the genotypic 
variation that causes a missense mutation in the gene coding 
for SOD1, it remains unclear as to whether affected animals 
will express phenotypic traits of DM during their lifetime 
(Awano et al. 2009; Coates et al. 2007). Previous studies have 
found that affected dogs may not exhibit clinical signs of DM, 
which suggests an incomplete penetrance. The incomplete 
penetrance  may  be  due  to  modifier  loci,  environmental 
factors, and/or death of affected dogs due to other causes 
before the clinical signs of DM manifest (Awano et al. 2009). 
Thus, the current literature suggests that an affected dog is 
at risk of developing clinical signs of DM and not that the 
dog will develop clinical signs of DM owing to incomplete 
penetrance (Awano et al. 2009; Coates et al. 2007; Coates & 
Wininger 2010).
TABLE 2: Summary of Boxer dogs genotyped for canine degenerative myelopathy.
Show Day Number of dogs at show Number of dogs tested Clear Carrier Affected
Day 1 33 24 15 8 1
Day 2 41 28 22 6 0
Total 74 52 37 14 1
Note: Clear is homozygous G/G, Carrier is heterozygous A/G and Affected is homozygous A/A.
FIGURE 1: A graphical demonstration of canine degenerative myelopathy heritage in a South African Boxer dog family.
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The  characteristic  clinical  signs  associated  with  DM  are 
attributed to the histopathological changes in the spinal cord 
thought to be due to the malformation of the SOD1 protein 
(Awano et al. 2009; Barclay & Haines 1994; Clemmons 1992; 
Coates et al. 2007; Coates & Wininger 2010; Cork et al. 1987; 
Johnston  et  al.  2000;  Miller  et  al.  2009;  Ogawa  et  al.  2011; 
Shelton et al. 2012; Tsai et al. 2012; Wininger et al. 2011). The 
SOD1 protein functions as a free radical scavenger within the 
central nervous system (Awano et al. 2009; Coates & Wininger 
2010).  The  missense  mutation  causes  the  SOD1  protein 
to fold incorrectly, which reduces its net negative charge. 
This  is  thought  to  be  the  cause  of  increased  intracellular 
accumulation and aggregation of this protein due to either 
reduced  repulsive  Coulombic  forces  or  increased  anionic 
membrane  surface  interaction  (Coates  &  Wininger  2010). 
These insoluble intracellular SOD1 aggregates are thought 
to  either  alter  intracellular  function  or  alter  the  enzyme 
substrate specificity, leading to toxic by-product production 
that causes the neurodegenerative changes associated with 
the disease (Coates & Wininger 2010). These characteristic 
histopathological lesions are considered diagnostic for DM, 
but samples are only taken during post-mortem examination 
(Awano et al. 2009; Coates & Wininger 2010; Johnston et al. 
2000; Miller et al. 2009). A tentative ante-mortem diagnosis 
may  be  made  on  characteristic  clinical  presentation 
in  the  absence  of  other  thoracolumbar  myelopathy 
aetiologies (Awano et al. 2009; Coates et al. 2007; Coates & 
Wininger 2010). 
Other  disease  processes  may  coexist  or  even  mimic  and 
confound a definitive diagnosis of DM, including degenerative 
lumbosacral  syndrome,  intervertebral  disc  disease,  spinal 
cord neoplasia and degenerative joint diseases such as hip 
dysplasia  or  cranial  cruciate  ligament  rupture  (Coates  & 
Wininger  2010).  The  historical  finding  of  cranial  cruciate 
ligament injury of the affected Boxer dog (3 years old) in the 
present study could indicate that there may be a link between 
these  coexisting  disease  processes  and  DM.  An  affected 
genotyped dog will greatly increase the suspicion of DM as 
being the definitive diagnosis only in patients presenting with 
the characteristic clinical signs. Other ante-mortal diagnostic 
tests have included magnetic resonance imaging (Coates & 
Wininger  2010),  computer  tomography  (Jones  et  al.  2005), 
cerebrospinal fluid examination (Kamishina et al. 2008; Oji 
et  al.  2007),  electrodiagnostic  testing  (Coates  et  al.  2007; 
Shelton  et  al.  2012)  and  neuromuscular  biopsies  (Awano 
et  al.  2009;  Coates  &  Wininger  2010;  Shelton  et  al.  2012), 
which may assist in definitively diagnosing DM; however, 
these  diagnostic  tests  are  not  always  positive  (Awano 
et al. 2009; Coates & Wininger 2010; Okada et al. 2009; Oliver 
1993). A definitive diagnosis of DM in the ante-mortal stage 
remains  a  challenge  (Coates  &  Wininger  2010).  The  link 
between  the  genotypic  expression  of  the  SOD1  mutation, 
the histopathological findings and the clinical manifestation 
cannot be ignored.
Previous studies have indicated that both normal and carrier 
dogs  present  with  clinical  signs  of  DM;  however,  these 
findings were not definitively diagnosed on histopathology and 
thus other possible aetiological causes cannot be excluded 
(Awano et al. 2009; Coates & Wininger 2010). Carrier dogs 
do  have  characteristic  immuno-histopathological  lesions 
that react with antibodies against the faulty SOD1 protein 
as  in  affected  dogs,  but  are  not  associated  with  clinical 
manifestation  of  the  disease  (Awano  et  al.  2009;  Barclay 
& Haines 1994; Coates & Wininger 2010), perhaps due to 
incomplete penetrance.
Degenerative  myelopathy  was  not  definitively  diagnosed  in 
any of the participating Boxer dogs in the present study and 
thus disease prevalence could not be calculated or estimated. 
The calculated point prevalence and overall prevalence were 
therefore based on detecting affected genotyped Boxer dogs 
in the FBCSA population. The overall prevalence of affected 
genotyped Boxer dogs was determined to be 0.23%, which is 
close to the current overall estimated prevalence of diagnosed 
DM of 0.19% (Coates et al. 2007; Shelton et al. 2012). These 
results indicate that DM should not be ignored as a possible 
differential  diagnosis  in  aged  Boxer  dogs  presenting  with 
pelvic  limb  abnormalities.  The  clinical  significance  of  this 
finding is difficult to appreciate at present as the affected dog 
did  have  a  history  of  pelvic  limb  pathology  characteristic 
of cranial cruciate ligament injury and not of DM. Due to 
the old age onset and progressive nature of the disease, the 
genotyping may become clinically significant in the future.
Conclusion
The present study concludes that genotyping of the missense 
mutation in Boxer dogs is possible in South Africa and that 
there are carrier and affected Boxer dogs in the South African 
population. This makes degenerative myelopathy a plausible 
diagnosis in aged dogs presenting with pelvic limb pathology. 
Owing to the late onset and insidious nature of the disease 
process, owners of Boxer dogs (and other commonly affected 
breeds) should consider genotyping prior to breeding.
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